Patients with symptomatic peripheral vascular disease are not eligible
Patients with history of active collagen vascular disease
Symptomatic peripheral vascular disease
No symptomatic peripheral arterial disease
Patients with known cardiac disease per the New York Heart Association definition such as myocardial infarction, severe or unstable angina, peripheral vascular disease, or congestive heart failure or peripheral vascular disease are not eligible
ischemic peripheral vascular disease, myocardial infarction within the past 6 months,
Known active collagen vascular disease
Active collagen vascular disease
systemic vascular disease or vasculitis
Vascular invasion
Any history of peripheral vascular infarction, including visceral infarction
Subject has a grade II or greater peripheral vascular disease
Clinically significant peripheral vascular disease
Symptomatic peripheral vascular disease
Clinically significant peripheral vascular disease
Symptomatic systemic vascular disease is defined as cardiovascular disease which prevents any procedure in MRI where ECG cannot be obtained (i.e. coronary disease). These patients must be excluded
Severe peripheral vascular disease that would preclude catheterization
Severe peripheral vascular disease that would preclude catheterization
History of stroke, coronary arterial disease, angina, or vascular disease
Subjects with prosthetic cardiac valves, vascular grafts, pacers, or other non-removable vascular foreign body, with the exception of coronary stents and peripheral stents;
Has arterial vascular involvement
Active collagen-vascular disease
Patients who had, within the past 6 months, a cardiovascular accident (CVA) or at risk for arterial thrombus such as severe peripheral vascular disease (PVD) and carotid artery disease (CAD)
Clinically significant peripheral vascular disease
Symptomatic peripheral vascular disease
Patients are excluded if they have symptomatic peripheral vascular disease
Patients with active vascular disease, either myocardial or peripheral (i.e. acute coronary syndrome, cerebral stroke, transient ischemic attack or arterial thrombosis or symptomatic peripheral vascular disease within the past 3 months);
Patients with known proliferative and/or vascular retinopathy;
Clinically significant peripheral vascular disease
Patients with clinically significant peripheral vascular disease
Symptomatic peripheral vascular disease
Has any condition known to effect wound healing, such as collagen vascular disease
No severe peripheral vascular disease
Symptomatic peripheral vascular disease
Significant vascular disease
Significant vascular disease
Subject either currently has central vascular access or is a candidate to receive central vascular access or peripheral vascular access for leukapheresis procedure.
Patients with symptomatic peripheral vascular disease are ineligible
Clinically significant peripheral vascular disease
Patients with symptomatic peripheral vascular disease are not eligible
Symptomatic arterial peripheral vascular disease
None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease
None of the following conditions within 6 months prior to enrollment: myocardial infarction, stroke or symptomatic peripheral vascular disease
Subjects with benign vascular tumor
Clinically significant peripheral vascular disease
Symptomatic peripheral vascular disease
Subject has a grade II or greater peripheral vascular disease
Clinically significant peripheral vascular disease
Significant cardiac or peripheral vascular arterial disease
Subject has peripheral vascular disease
Clinically significant peripheral vascular disease
History of significant vascular disease.
Significant vascular disease
Severe peripheral vascular disease in subjects whose Study Lesions are located in an extremity
Significant vascular disease.
CTCAE grade 3 or greater peripheral vascular disease
Neurologic, metabolic, or vascular diseases that may negatively impact erectile function, such as: diabetes mellitus, peripheral vascular disease, coronary artery disease, stroke, multiple sclerosis, Parkinsonâ€™s disease, multiple systems atrophy, epilepsy, or spinal cord injury.
Vascular disease resulting in clinically apparent compromise in blood flow to the treatment extremity (i.e. peripheral vascular disease with diminished pulses, venous insufficiency with clinical evidence of vascular congestion)
Active collagen vascular disease
Patients with collagen vascular disease are excluded
No symptomatic peripheral vascular obstructions
Previous diagnosis of collagen vascular disorder or vasculitis
The subject has a history of peripheral vascular disease
A history of cardiovascular disease, hypertension, or peripheral arterial/vascular disease;
Subject has known lympho-vascular invasion
Hospitalization in the past 2 months for any cardiovascular disease, including but not limited to:\r\n* Angina\r\n* Myocardial infarction\r\n* Peripheral vascular disease\r\n* Stroke
Participants with known active collagen vascular disease
Measurable hepatic disease and/or presence of vascular tumor thrombosis
Participants with known active collagen vascular disease
Have collagen vascular disease
